Meeting News

Patients prefer combination prophylactic drop

Helga P. Sandoval

SAN DIEGO — Patients treated with a combination drop therapy as prophylaxis after cataract surgery reported less stinging and burning and a higher satisfaction rate than patients treated with a standard prophylactic treatment of NSAID, antibiotic and steroid, according to a speaker here.

“LessDrops is a prophylactic treatment alternative with a high patient preference. There was no difference between the two groups in macular thickness and pachymetry at day 30. There were no unanticipated adverse events,” Helga P. Sandoval, MD, MSCR, said at the American Society of Cataract and Refractive Surgery annual meeting.

Sandoval presented initial data of a study assessing the efficacy of a compounded combination drop therapy, LessDrops (Imprimis), containing gatifloxacin 0.5%, bromfenac 0.075% and prednisolone acetate 1% in one eye drop. The efficacy of the combination drop was compared with the standard prophylactic treatment of the same individual components in three drops. Outcomes were evaluated after cataract surgery on days 1, 15 and 30.

At day 30, there was no statically significant difference in macular thickness or pachymetry between the two groups, and postoperative inflammation was minimal at all time points.

All patients in both groups reported a burning sensation, but more patients in the control group reported both burning and stinging compared with the combination group.

“All patients were very satisfied and there was no difference between the control and LessDrops groups, but 100% of the patients preferred to use the LessDrops because it is just the three drops combined into one drop used three times a day,” Sandoval said. – by Robert Linnehan

 

Reference:

Sandoval HP. Combination drop therapy used as prophylactic treatment compared to standard drop regimen after routine phacoemulsification. Presented at: American Society of Cataract and Refractive Surgery annual meeting; May 3-7, 2019; San Diego.

Disclosure: Sandoval reports no relevant financial disclosures. The investigator-initiated trial was supported by Imprimis.

Helga P. Sandoval

SAN DIEGO — Patients treated with a combination drop therapy as prophylaxis after cataract surgery reported less stinging and burning and a higher satisfaction rate than patients treated with a standard prophylactic treatment of NSAID, antibiotic and steroid, according to a speaker here.

“LessDrops is a prophylactic treatment alternative with a high patient preference. There was no difference between the two groups in macular thickness and pachymetry at day 30. There were no unanticipated adverse events,” Helga P. Sandoval, MD, MSCR, said at the American Society of Cataract and Refractive Surgery annual meeting.

Sandoval presented initial data of a study assessing the efficacy of a compounded combination drop therapy, LessDrops (Imprimis), containing gatifloxacin 0.5%, bromfenac 0.075% and prednisolone acetate 1% in one eye drop. The efficacy of the combination drop was compared with the standard prophylactic treatment of the same individual components in three drops. Outcomes were evaluated after cataract surgery on days 1, 15 and 30.

At day 30, there was no statically significant difference in macular thickness or pachymetry between the two groups, and postoperative inflammation was minimal at all time points.

All patients in both groups reported a burning sensation, but more patients in the control group reported both burning and stinging compared with the combination group.

“All patients were very satisfied and there was no difference between the control and LessDrops groups, but 100% of the patients preferred to use the LessDrops because it is just the three drops combined into one drop used three times a day,” Sandoval said. – by Robert Linnehan

 

Reference:

Sandoval HP. Combination drop therapy used as prophylactic treatment compared to standard drop regimen after routine phacoemulsification. Presented at: American Society of Cataract and Refractive Surgery annual meeting; May 3-7, 2019; San Diego.

Disclosure: Sandoval reports no relevant financial disclosures. The investigator-initiated trial was supported by Imprimis.

    See more from American Society of Cataract and Refractive Surgery Meeting